Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Angle Share News (AGL)
AGL Share
Price
AGL Share
News
AGL Share
Chat
AGL Share
Trades37
AGL
Live RNS
AGL Share
Charts
AGL Broker
Ratings
AGL Directors
Deals
AGL Financial
Diary
AGL
Fundamentals
AGL Short
Positions
AGL
Media
AGL Company
Research
AGL Company
Timeline
- There is currently no data for AGL
IN BRIEF: Angle highlights supportive data for DNA analysis tool
Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.
Current stock price: 17.85 pence, down 8.5% in London on Monday
12-month change: down 42%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Latest AGL News
- TRADING UPDATES: Futura signs development deal; UKOG gets day in court
4 Mar 2021 - AIM WINNERS & LOSERS: Futura Medical rises on financing transaction
4 Mar 2021 - Angle Shares Jump On Recent Parsortix System Research Results
18 Feb 2021 - IN BRIEF: Angle Says Athens University Study Shows Value Of Parsortix
8 Feb 2021 - TRADING UPDATES: Character Extends Peppa Pig Deal; Dekel Raises Cash
29 Jan 2021 - Angle Reports Parsortix System Can Isolate Circulating Tumour Cells
20 Jan 2021 - LONDON AIM WINNERS & LOSERS: Sabien Sinks On Ptarmigan Deal Withdrawal
20 Jan 2021 - DIRECTOR DEALINGS: Angle Chair And Finance Director Buys 60,000 Shares
3 Nov 2020
Related News
IN BRIEF: Angle names Peter Collins as interim CEO
(Alliance News) - Angle PLC - Guildford, England-based liquid biopsy company, which is to be renamed CelLBxHealth PLC - Appoints Peter Collins as inte...
Angle touts planned name and strategy change, Groen turns executive
(Alliance News) - Angle PLC shares fell on Wednesday, after it announced plans to rename itself CelLBxHealth PLC and "[pursue] a revised strategy", wi...
IN BRIEF: Angle CEO and finance lead step down after shareholder talks
Angle PLC - Guildford, England-based liquid biopsy company - Says that, following talks with an unnamed "significant shareholder", Chief Executive Off...
Angle News
TRADING UPDATES: Futura signs development deal; UKOG gets day in court
TRADING UPDATES: Futura signs development deal; UKOG gets day in court
AIM WINNERS & LOSERS: Futura Medical rises on financing transaction
AIM WINNERS & LOSERS: Futura Medical rises on financing transaction
Angle Shares Jump On Recent Parsortix System Research Results
Angle Shares Jump On Recent Parsortix System Research Results
IN BRIEF: Angle Says Athens University Study Shows Value Of Parsortix
IN BRIEF: Angle Says Athens University Study Shows Value Of Parsortix
TRADING UPDATES: Character Extends Peppa Pig Deal; Dekel Raises Cash
TRADING UPDATES: Character Extends Peppa Pig Deal; Dekel Raises Cash
Angle Reports Parsortix System Can Isolate Circulating Tumour Cells
Angle Reports Parsortix System Can Isolate Circulating Tumour Cells
LONDON AIM WINNERS & LOSERS: Sabien Sinks On Ptarmigan Deal Withdrawal
LONDON AIM WINNERS & LOSERS: Sabien Sinks On Ptarmigan Deal Withdrawal
DIRECTOR DEALINGS: Angle Chair And Finance Director Buys 60,000 Shares
DIRECTOR DEALINGS: Angle Chair And Finance Director Buys 60,000 Shares
Follow the stocks
